SCHEMBL241675

SCHEMBL241675

NC(=O)Nc1ncc[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL29001621 0.98 FDPS (0.44)
Acetic Acid SCHEMBL29250458 0.93 FFAR2 (0.43)
Fluorobenzene SCHEMBL27924969 0.85 CYP3A4 (0.44)
SCHEMBL8819697 0.83 FDPS (0.48)
SCHEMBL7342758 0.83 FDPS (0.48)
SCHEMBL5333624 0.81 FDPS (0.41)
SCHEMBL170782 0.81
SCHEMBL1906545 0.79
SCHEMBL2018066 0.79
SCHEMBL28057416 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 323 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116102688-B Zwitterionic polymer hydrogel and preparation method and application thereof 武汉科技大学 2025-03-04 CN claimed
CN-116102688-A Zwitterionic polymer hydrogel and preparation method and application thereof 武汉科技大学 2023-05-12 CN claimed
CN-112844472-A Preparation method and application of chiral imidazole urea catalyst 深圳飞扬兴业科技有限公司 2021-05-28 CN claimed
CN-107922611-B Imidazoyl urea polymers and their use in metal or metal alloy plating bath compositions 埃托特克德国有限公司 2020-11-24 CN claimed
EP-3708676-A1 PRESERVATION OF FETAL NUCLEIC ACIDS IN MATERNAL PLASMA Streck, Inc. (US) 2020-09-16 EP claimed
WO-2016010984-A2 COMPOSITIONS AND METHODS FOR TREATING ROSACEA TISSUE TECH, INC. (US) 2016-01-21 WO claimed
US-20160008295-A1 COMPOSITIONS AND METHODS FOR TREATING ROSACEA TISSUE TECH, INC. 2016-01-14 US claimed
EP-2626438-A1 Preservation of fetal nucleic acids in maternal plasma Streck Inc. (US) 2013-08-14 EP claimed
US-20120295940-A1 COMPOSITIONS FOR TREATING MASTITIS NOBLE ION, LLC (US) 2012-11-22 US claimed
US-20100298386-A1 COMPOSITIONS AND METHODS FOR TREATING MASTITIS BYOCOAT ENTERPRISES, INC. (PR) 2010-11-25 US claimed
US-20090233914-A1 Composition for treatment of nail infections ONDINE INTERNATIONAL, LTD. 2009-09-17 US claimed
US-20090170876-A1 Novel Topical Formulations of Flucytosine CAMARGO PHARMACEUTICAL SERVICES, LLC (US) 2009-07-02 US claimed
WO-2009045456-A1 COMPOSITIONS AND METHODS FOR TREATING MASTITIS BYOCOAT ENTERPRISES, INC. (PR) 2009-04-09 WO claimed
US-20090068287-A1 Novel topical formulations of flucytosine and uses thereof CAMARGO PHARMACEUTICAL SERVICES LLC 2009-03-12 US claimed
WO-2008109424-A1 COMPOSITION, THERAPY AND DEVICE FOR TREATMENT OF NAIL INFECTIONS ONDINE INTERNATIONAL LTD. (BB) 2008-09-12 WO claimed
US-5922331-A PROTECTION AGAINST LUMPINESS, EDEMA AND OTHER EFFECTS FO LIPOSUCTION AND COSMETIC SURGERY CHANEL, INC. (US) 1999-07-13 US claimed
EP-0029663-B1 N-ARYL-N'-IMIDAZOL-2-YLUREAS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM McNeilab, Inc. (US) 1984-04-18 EP claimed
EP-0029663-A1 N-aryl-N'-imidazol-2-ylureas, process for their preparation and pharmaceutical compositions containing them McNeilab, Inc. (US) 1981-06-03 EP claimed
US-4265900-A HYPOTENSIVE, ANTISECRETORY, ANTIDIARRHEA MCNEILAB, INC. (US) 1981-05-05 US claimed
JP-63030471-A None JP disclosed
EP-4572738-A1 SOFT-FOCUS COSMETICS COMPOSITIONS AND METHODS FOR REDUCING THE APPEARANCE OF SKIN IMPERFECTIONS ELC Management LLC (US) 2025-06-25 EP disclosed
CN-119663385-A Leveling agent and preparation method thereof, copper electroplating solution and copper electroplating method 广东东硕科技有限公司 2025-03-21 CN disclosed
CN-116102688-B Zwitterionic polymer hydrogel and preparation method and application thereof 武汉科技大学 2025-03-04 CN disclosed
CN-119060277-A Latent curing agent and preparation method and application thereof 株洲市弘大新材料有限公司 2024-12-03 CN disclosed
US-20240299561-A1 HISTIDINE-SELECTIVE POLYMER REAGENTS NEKTAR THERAPEUTICS 2024-09-12 US disclosed
EP-4355371-A1 HISTIDINE-SELECTIVE POLYMER REAGENTS Nektar Therapeutics (US) 2024-04-24 EP disclosed
WO-2024039497-A1 SOFT-FOCUS COSMETICS COMPOSITIONS AND METHODS FOR REDUCING THE APPEARANCE OF SKIN IMPERFECTIONS ELC MANAGEMENT LLC (US) 2024-02-22 WO disclosed
CN-117425470-A Antiperspirant compositions 科蒂公司 2024-01-19 CN disclosed
CN-116940326-A Antiperspirant compositions 科蒂公司 2023-10-24 CN disclosed
CN-116035935-B Anti-dandruff and antipruritic composition and preparation method thereof, shampoo and preparation method thereof, and medicament 肇庆迪彩日化科技有限公司 2023-09-19 CN disclosed
EP-4032930-B1 BIURET-BASED QUATERNIZED POLYMERS AND THEIR USE IN METAL OR METAL ALLOY PLATING BATHS ATOTECH DEUTSCHLAND GMBH & CO KG (DE) 2023-08-30 EP disclosed
CN-116621781-A Preparation method of 2- (3-nitrophenyl) -4, 5-dihydro-1H-imidazoline 济南鸿湾生物技术有限公司 2023-08-22 CN disclosed
CN-116355172-A Polyurethane elastomer and preparation method thereof 东华大学 2023-06-30 CN disclosed
CN-116367811-A Antiperspirant compositions 科蒂公司 2023-06-30 CN disclosed
CN-116042114-B Holographic anti-counterfeiting packaging film and printing process thereof 汕头市恒顺包装材料有限公司 2023-06-20 CN disclosed
CN-116102688-A Zwitterionic polymer hydrogel and preparation method and application thereof 武汉科技大学 2023-05-12 CN disclosed
CN-116042114-A Holographic anti-counterfeiting packaging film and printing process thereof 汕头市恒顺包装材料有限公司 2023-05-02 CN disclosed
CN-116035935-A Anti-dandruff and antipruritic composition and preparation method thereof, shampoo and preparation method thereof, and medicament 肇庆迪彩日化科技有限公司 2023-05-02 CN disclosed
CN-115926109-A Imidazole urea bond self-healing elastomer based on copper ion coordination 东华大学 2023-04-07 CN disclosed
WO-2022266498-A1 HISTIDINE-SELECTIVE POLYMER REAGENTS NEKTAR THERAPEUTICS (US) 2022-12-22 WO disclosed
WO-2022157292-A1 BIURET-BASED QUATERNIZED POLYMERS AND THEIR USE IN METAL OR METAL ALLOY PLATING BATHS Atotech Deutschland GmbH & Co. KG (DE) 2022-07-28 WO disclosed
EP-4032930-A1 BIURET-BASED QUATERNIZED POLYMERS AND THEIR USE IN METAL OR METAL ALLOY PLATING BATHS Atotech Deutschland GmbH & Co. KG (DE) 2022-07-27 EP disclosed
WO-2022125592-A1 METHODS OF MAKING WATER-SOLUBLE PROTEIN FORMED IN A BACTERIAL EXPRESSION SYSTEM, COMPOSITIONS, AND METHODS OF USE THEREOF The Research Foundation for the State Universtiy of New York (US) 2022-06-16 WO disclosed
CN-111995683-B anti-PD-L1 protein monoclonal antibody, cell strain, preparation method and application thereof 福州迈新生物技术开发有限公司 2022-03-11 CN disclosed
CN-107406339-B Method and apparatus for producing alpha-olefin oligomer 三菱化学株式会社 2021-10-26 CN disclosed
US-11130737-B2 Multifunctional aminoquinoline therapeutic agents LOHOCLA RESEARCH CORPORATION (US) 2021-09-28 US disclosed
EP-3846813-A1 ANALGESIC COMPOSITIONS Lohocla Research Corporation (US) 2021-07-14 EP disclosed
EP-1613613-B1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS GENZYME CORP (US) 2021-06-02 EP disclosed
US-10953021-B2 Topical compositions of flunisolide and methods of treatment LUPIN LIMITED (IN) 2021-03-23 US disclosed
CN-111995683-A anti-PD-L1 protein monoclonal antibody, cell strain, preparation method and application thereof 福州迈新生物技术开发有限公司 2020-11-27 CN disclosed
CN-107922611-B Imidazoyl urea polymers and their use in metal or metal alloy plating bath compositions 埃托特克德国有限公司 2020-11-24 CN disclosed
CN-107074679-B Method and apparatus for producing alpha-olefin oligomer 三菱化学株式会社 2020-11-17 CN disclosed
CN-107406345-B Process for producing alpha-olefin oligomer 三菱化学株式会社 2020-08-11 CN disclosed
CN-107428629-B α -Process for producing olefin oligomer 三菱化学株式会社 2020-07-28 CN disclosed
US-20200095204-A1 MULTIFUNCTIONAL AMINOQUINOLINE THERAPEUTIC AGENTS LOHOCLA RESEARCH CORPORATION 2020-03-26 US disclosed
US-20190321395-A1 TREATMENT OF PSORIASIS, SEBORRHEIC DERMATITIS, AND ECZEMA OF THE HEAD AND NECK Oread Therapeutics 2019-10-24 US disclosed
US-10441522-B2 Surfactant-containing cleaning agent compositions with specific combinations of four preservatives HENKEL AG & CO. KGAA (DE) 2019-10-15 US disclosed
US-10435371-B2 Multifunctional aminoquinoline therapeutic agent LOHOCLA RESEARCH CORPORATION (US) 2019-10-08 US disclosed
US-10391088-B2 Analgesic compositions LOHOCLA RESEARCH CORPORATION (US) 2019-08-27 US disclosed
US-10357442-B2 Surfactant-containing cleansing agents with at least four different preservatives HENKEL AG & CO. KGAA (DE) 2019-07-23 US disclosed
US-20190099412-A1 ANALGESIC COMPOSITIONS LOHOCLA RESEARCH CORPORATION 2019-04-04 US disclosed
US-20190092731-A1 MULTIFUNCAIONAL AMINOQUINOLINE THERAPEUTIC AGENT LOHOCLA RESEARCH CORPORATION 2019-03-28 US disclosed
US-10155788-B2 Cationic steroidal antimicrobial prodrug compositions and uses thereof BRIGHAM YOUNG UNIVERSITY (US) 2018-12-18 US disclosed
US-10112905-B2 Multifunctional aminoquinoline therapeutic agents LOHOCLA RESEARCH CORPORATION (US) 2018-10-30 US disclosed
CN-107428629-A Process for producing alpha-olefin oligomer 三菱化学株式会社 2017-12-01 CN disclosed
US-9827195-B2 Fatty acid pharmaceutical foam STIEFEL RESEARCH AUSTRALIA PTY LTD (AU) 2017-11-28 US disclosed
CN-107406339-A Method and apparatus for producing alpha-olefin oligomer 三菱化学株式会社 2017-11-28 CN disclosed
CN-107406345-A Process for producing alpha-olefin oligomer 三菱化学株式会社 2017-11-28 CN disclosed
EP-3209271-A1 METHOD OF IMPROVED VOLUME AND COMBABILITY USING PERSONAL CARE COMPOSITION COMPRISING A PRE-EMULSIFIED FORMULATION The Procter and Gamble Company (US) 2017-08-30 EP disclosed
CN-107074679-A Method and apparatus for producing alpha-olefin oligomer 三菱化学株式会社 2017-08-18 CN disclosed
US-20170204064-A1 MULTIFUNCTIONAL AMINOQUINOLINE THERAPEUTIC AGENTS LOHOCLA RESEARCH CORPORATION 2017-07-20 US disclosed
US-20170172871-A1 PROPELLANT-INCLUDING DEODORANTS AND/OR ANTIPERSPIRANTS COMPRISING AT LEAST TWO DIFFERENT PRESERVATIVES HENKEL AG & CO. KGAA (DE) 2017-06-22 US disclosed
US-20170172894-A1 PROPELLANT-FREE DEODORANTS AND/OR ANTIPERSPIRANTS COMPRISING AT LEAST TWO DIFFERENT PRESERVATIVES HENKEL AG & CO. KGAA (DE) 2017-06-22 US disclosed
US-20170172872-A1 PROPELLANT-FREE DEODORANTS AND/OR ANTIPERSPIRANTS HAVING SPECIFIC PRESERVATIVE-AGENT COMBINATIONS HENKEL AG & CO. KGAA (DE) 2017-06-22 US disclosed
US-20170172873-A1 PROPELLANT-FREE DEODORANTS AND/OR ANTIPERSPIRANTS HAVING SPECIFIC PRESERVATIVE-AGENT COMBINATIONS HENKEL AG & CO. KGAA (DE) 2017-06-22 US disclosed
US-20170165167-A1 SURFACTANT-CONTAINING CLEANING AGENT COMPOSITIONS WITH SPECIFIC PRESERVATIVE COMBINATIONS HENKEL AG & CO. KGAA (DE) 2017-06-15 US disclosed
US-20170165168-A1 EMULSIONS INCLUDING AT LEAST ONE SPECIAL PRESERVATIVE COMBINATION HENKEL AG & CO. KGAA (DE) 2017-06-15 US disclosed
US-20170165169-A1 SURFACTANT-CONTAINING CLEANSING AGENTS WITH AT LEAST THREE DIFFERENT PRESERVATIVES HENKEL AG & CO. KGAA (DE) 2017-06-15 US disclosed
EP-3157523-A1 MULTIFUNCTIONAL AMINOQUINOLINE THERAPEUTIC AGENTS Lohocla Research Corporation (US) 2017-04-26 EP disclosed
US-9314524-B2 Topical formulations of Flucytosine CALLA THERAPEUTICS LLC (US) 2016-04-19 US disclosed
WO-2016057635-A1 CATIONIC STEROIDAL ANTIMICROBIAL PRODRUG COMPOSITIONS AND USES THEREOF SAVAGE PAUL B (US) 2016-04-14 WO disclosed
US-20160096864-A1 CATIONIC STEROIDAL ANTIMICROBIAL PRODRUG COMPOSITIONS AND USES THEREOF BRIGHAM YOUNG UNIVERSITY (US) 2016-04-07 US disclosed
WO-2016054450-A1 METHOD OF IMPROVED VOLUME AND COMBABILITY USING PERSONAL CARE COMPOSITION COMPRISING A PRE-EMULSIFIED FORMULATION THE PROCTER & GAMBLE COMPANY (US) 2016-04-07 WO disclosed
WO-2016010984-A2 COMPOSITIONS AND METHODS FOR TREATING ROSACEA TISSUE TECH, INC. (US) 2016-01-21 WO disclosed
EP-2968572-A1 TOPICAL COMPOSITIONS OF FLUNISOLIDE AND METHODS OF TREATMENT Medicis Pharmaceutical Corporation (US) 2016-01-20 EP disclosed
US-20160008295-A1 COMPOSITIONS AND METHODS FOR TREATING ROSACEA TISSUE TECH, INC. 2016-01-14 US disclosed
WO-2015195943-A1 MULTIFUNCTIONAL AMINOQUINOLINE THERAPEUTIC AGENTS LOHOCLA RESEARCH CORPORATION (US) 2015-12-23 WO disclosed
US-20150335617-A1 METHODS AND COMPOSITIONS FOR TREATING PSORIASIS NATROGEN THERAPEUTICS INTERNATIONAL, INC. 2015-11-26 US disclosed
CN-102781884-B Process for producing alpha-olefin oligomer MITSUBISHI CHEMICAL CORP. (JP) 2015-11-25 CN disclosed
CN-104926589-A Process for producing alpha-olefin oligomer MITSUBISHI CHEM CORP 2015-09-23 CN disclosed
US-20150209280-A1 FATTY ACID PHARMACEUTICAL FOAM STIEFEL RES AUSTRALIA PTY LTD (AU) 2015-07-30 US disclosed
US-20150202139-A1 ANTI-AGING SKINCARE PRODUCTS MD SOLARCIENCES CORP. (US) 2015-07-23 US disclosed
EP-2157091-B1 Inhibitors of phosphatidylinositol 3-kinase NOVARTIS AG (CH) 2015-06-10 EP disclosed
US-9023863-B2 Fatty acid pharmaceutical foam STIEFEL RESEARCH AUSTRALIA PTY LTD (AU) 2015-05-05 US disclosed
CN-104434572-A Mascara WANG YUMEI 2015-03-25 CN disclosed
WO-2014145067-A1 TOPICAL COMPOSITIONS OF FLUNISOLIDE AND METHODS OF TREATMENT MEDICIS PHARMACEUTICAL CORPORATION (US) 2014-09-18 WO disclosed
US-20140274982-A1 TOPICAL COMPOSITIONS OF FLUNISOLIDE AND METHODS OF TREATMENT MEDICIS PHARMACEUTICAL CORPORATION (US) 2014-09-18 US disclosed
CN-101864027-B Copolymers and their use in personal care compositions CIBA SPECIALTY CHEMICALS HODIN 2014-08-27 CN disclosed
US-8765934-B2 Methods for conjugating nucleic acids with small molecules KAOHSIUNG MEDICAL UNIVERSITY (TW) 2014-07-01 US disclosed
US-20130338098-A1 Topical Analgesic Compositions Containing Aliphatic Polyamines and Methods of Using Same DERMAL THERAPY (BARBADOS) INC. (BB) 2013-12-19 US disclosed
EP-2322525-B1 Purine derivatives for use as adenosin A2A receptor agonists NOVARTIS AG (CH) 2013-09-18 EP disclosed
US-20130225581-A1 NITROGEN-CONTAINING AROMATIC HETEROCYCLIC DERIVATIVE KYOWA HAKKO KIRIN CO., LTD (JP) 2013-08-29 US disclosed
US-20130172349-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE NOVARTIS AG (CH) 2013-07-04 US disclosed
US-8470813-B2 Thiazoline and oxazoline derivatives and their methods of use ABBVIE INC. (US) 2013-06-25 US disclosed
EP-2594566-A1 NITROGENATED AROMATIC HETEROCYCLIC RING DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2013-05-22 EP disclosed
US-8445509-B2 Fused heterocyclic derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-21 US disclosed
CN-103003262-A Nitrogenated aromatic heterocyclic ring derivative KYOWA HAKKO KIRIN CO LTD 2013-03-27 CN disclosed
US-8404684-B2 Inhibitors of phosphatidylinositol 3-kinase NOVARTIS AG (CH) 2013-03-26 US disclosed
US-8318750-B2 Organic compounds NOVARTIS AG (NL) 2012-11-27 US disclosed
US-20120295940-A1 COMPOSITIONS FOR TREATING MASTITIS NOBLE ION, LLC (US) 2012-11-22 US disclosed
CN-102781884-A Process for producing alpha-olefin oligomer MITSUBISHI CHEM CORP 2012-11-14 CN disclosed
US-8304557-B2 Fused heterocycle derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-06 US disclosed
US-8258141-B2 Organic compounds NOVARTIS AG (CH) 2012-09-04 US disclosed
EP-1805181-B1 PURINE DERIVATIVES FOR USE AS ADENOSIN A-2A RECEPTOR AGONISTS NOVARTIS AG (CH) 2012-08-29 EP disclosed
EP-2046121-B1 FATTY ACID PHARMACEUTICAL FOAM STIEFEL RES AUSTRALIA PTY LTD (AU) 2012-08-22 EP disclosed
US-20120177573-A1 METHODS FOR CONJUGATING NUCLEIC ACIDS WITH SMALL MOLECULES KAOHSIUNG MEDICAL UNIVERSITY (TW) 2012-07-12 US disclosed
US-8163754-B2 inflammatory or obstructive airways diseases; in combination with an antiinflammatory, bronchodilatory, antihistamine or anti-tussive; N-[4-(6-Amino-2-phenethylamino-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide NOVARTIS AG (CH) 2012-04-24 US disclosed
US-20120070518-A1 METHODS AND COMPOSITIONS FOR TREATING PSORIASIS NATROGEN THERAPEUTICS INTERNATIONAL, INC. (US) 2012-03-22 US disclosed
EP-2013211-B1 PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS NOVARTIS AG (CH) 2012-03-14 EP disclosed
US-20120004212-A1 ORGANIC COMPOUNDS NOVARTIS AG 2012-01-05 US disclosed
US-20120004247-A1 ORGANIC COMPOUNDS NOVARTIS AG 2012-01-05 US disclosed
EP-1633368-B1 FOAMABLE PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING A DISORDER STIEFEL LABORATORIES (US) 2011-11-16 EP disclosed
WO-2011066182-A3 SOCS3 INHIBITION PROMOTES CNS NEURON REGENERATION CHILDREN'S MEDICAL CENTER CORPORATION (US) 2011-10-27 WO disclosed
US-20110201578-A1 COMPOSITION AND METHODS FOR THE TREATMENT OF PSEUDOFOLLICULITIS BARBAE AND SKIN IRRITATION MAN-CHEM, LLC 2011-08-18 US disclosed
US-7998990-B2 5-phenyl-thiazol-2-yl-urea derivatives and use as PI3 kinase inhibitors NOVARTIS AG (CH) 2011-08-16 US disclosed
US-20110124693-A1 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES NOVARTIS AG (CH) 2011-05-26 US disclosed
US-20110124624-A1 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES NOVARTIS AG (CH) 2011-05-26 US disclosed
EP-2322525-A1 Purine derivatives for use as adenosin A2A receptor agonists Novartis AG (CH) 2011-05-18 EP disclosed
US-20110105535-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE NOVARTIS AG 2011-05-05 US disclosed
US-20110091552-A1 Use of Bcl Inhibitors for the Treatment of Scarring Caused By Cutaneous Wounds, Burns and Abrasions MCCAFFREY TIM 2011-04-21 US disclosed
US-20110092493-A1 Dose-controlled transdermal promethazine compositions and methods of use LEVI CLARK 2011-04-21 US disclosed
EP-2292619-A1 Purine derivatives for use as adenonsin A-2A receptor agonists Novartis AG (CH) 2011-03-09 EP disclosed
US-7902375-B2 Antiallergens; antiarthritic agents; psoriasis; inflammatory bowel disorders; Crohn's disease; sepsis ; antiproliferative agents; anticancer agents; transplant rejection; stroke; antidiabetic agents; restenosis NOVARTIS AG (CH) 2011-03-08 US disclosed
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-24 US disclosed
US-20110021630-A1 METHOD FOR TREATING WOUNDS BY ADMINISTERING FULLERENES KEPLEY CHRISTOPHER L 2011-01-27 US disclosed
US-20110009486-A1 METHOD FOR TREATING PRURITUS BY ADMINISTERING FULLERENES LUNA INNOVATIONS INCORPORATED (US) 2011-01-13 US disclosed
US-20110003773-A1 USING FULLERENES TO ENHANCE AND STIMULATE HAIR GROWTH LUNA INNOVATIONS INCORPORATED (US) 2011-01-06 US disclosed
US-20100298386-A1 COMPOSITIONS AND METHODS FOR TREATING MASTITIS BYOCOAT ENTERPRISES, INC. (PR) 2010-11-25 US disclosed
US-7833331-B2 Non-toxic corrosion-protection pigments based on cobalt UNIVERSITY OF DAYTON (US) 2010-11-16 US disclosed
US-20100286126-A1 Organic Compounds NOVARTIS AG (CH) 2010-11-11 US disclosed
US-7829107-B2 Foamable pharmaceutical compositions and methods for treating a disorder STIEFEL LABORATORIES, INC. (US) 2010-11-09 US disclosed
US-20100266517-A1 Two-Coat Cosmetic Compositions AVON PRODUCTS. INC. (US) 2010-10-21 US disclosed
CN-101864027-A Multipolymer and the application in personal care composition thereof CIBA SPECIALTY CHEMICALS HODIN 2010-10-20 CN disclosed
US-7799810-B2 Organic compounds NOVARTIS AG (CH) 2010-09-21 US disclosed
US-7789958-B2 Non-toxic corrosion-protection pigments based on manganese UNIVERSITY OF DAYTON (US) 2010-09-07 US disclosed
US-20100190776-A1 Thiazoline and Oxazoline Derivatives and Their Methods of Use ABBOTT LABORATORIES (US) 2010-07-29 US disclosed
US-20100120865-A1 Organic compounds NOVARTIS AG (CH) 2010-05-13 US disclosed
WO-2010036945-A2 NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2010-04-01 WO disclosed
US-7683084-B2 Thiazoline and oxazoline derivatives and their methods of use ABBOTT LABORATORIES (US) 2010-03-23 US disclosed
EP-2162445-A1 HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2010-03-17 EP disclosed
EP-2157091-A1 Inhibitors of phosphatidylinositol 3-kinase Novartis AG (CH) 2010-02-24 EP disclosed
CN-100577726-C Polymer emulsions resistant to biodeterioration WACKER CHEMICAL CORP 2010-01-06 CN disclosed
WO-2009136663-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-12 WO disclosed
US-20090281127-A1 Organic Compounds NOVARTIS AG (CH) 2009-11-12 US disclosed
EP-1622897-B1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE NOVARTIS AG (CH) 2009-10-14 EP disclosed
US-20090240045-A1 Organic Compounds NOVARTIS AG 2009-09-24 US disclosed
US-20090234132-A1 5-PHENYL-THIAZOL-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2009-09-17 US disclosed
US-20090234270-A1 Therapy and device for treatment of nail infections ONDINE INTERNATIONAL, LTD. 2009-09-17 US disclosed
US-20090233914-A1 Composition for treatment of nail infections ONDINE INTERNATIONAL, LTD. 2009-09-17 US disclosed
WO-2009114089-A2 USING FULLERENES TO ENHANCE AND STIMULATE HAIR GROWTH LUNA INNOVATIONS INCORPORATED (US) 2009-09-17 WO disclosed
WO-2009114084-A2 METHOD FOR TREATING WOUNDS BY ADMINISTERING FULLERENES LUNA INNOVATIONS INCORPORATED (US) 2009-09-17 WO disclosed
WO-2009114087-A2 A METHOD FOR TREATING PRURITUS BY ADMINISTERING FULLERENES LUNA INNOVATIONS INCORPORATED (US) 2009-09-17 WO disclosed
EP-2089052-A1 PEG LINKER COMPOUNDS AND BIOLOGICALLY ACTIVE CONJUGATES THEREOF Peg Biosciences (US) 2009-08-19 EP disclosed
US-20090170876-A1 Novel Topical Formulations of Flucytosine CAMARGO PHARMACEUTICAL SERVICES, LLC (US) 2009-07-02 US disclosed
US-7553646-B2 Microbial sulfoxidation and amidation of benzhdrylsulfanyl carboxylic acids and uses thereof UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2009-06-30 US disclosed
US-20090163628-A1 NON-TOXIC CORROSION-PROTECTION PIGMENTS BASED ON COBALT STURGILL JEFFREY ALLEN 2009-06-25 US disclosed
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
US-20090105476-A1 Organic Compounds NOVARTIS AG 2009-04-23 US disclosed
US-20090105195-A1 COMPOSITION COMPRISING MICROBICIDAL ACTIVE INGREDIENTS NUGENE BIOPHARMA, INC 2009-04-23 US disclosed
EP-1689391-B1 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES NOVARTIS AG (CH) 2009-04-22 EP disclosed
US-20090099214-A1 Organic Compounds NOVARTIS AG 2009-04-16 US disclosed
EP-2046121-A2 FATTY ACID PHARMACEUTICAL FOAM Stiefel Research Australia Pty Ltd (AU) 2009-04-15 EP disclosed
WO-2009045456-A1 COMPOSITIONS AND METHODS FOR TREATING MASTITIS BYOCOAT ENTERPRISES, INC. (PR) 2009-04-09 WO disclosed
EP-2038278-A2 THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE Abbott Laboratories (US) 2009-03-25 EP disclosed
EP-2035413-A2 THIAZOLYL UREA DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS Novartis AG (CH) 2009-03-18 EP disclosed
US-20090068287-A1 Novel topical formulations of flucytosine and uses thereof CAMARGO PHARMACEUTICAL SERVICES LLC 2009-03-12 US disclosed
EP-1318801-B1 TOPICAL ANALGESIC COMPOSITIONS CONTAINING ALIPHATIC POLYAMINES AND METHODS OF USING SAME DERMAL THERAPY BARBADOS INC (BB) 2009-03-11 EP disclosed
EP-2029562-A1 5-PHENYL-THIAZ0L-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS Novartis Ag (CH) 2009-03-04 EP disclosed
EP-2018381-A2 USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS Novartis AG (CH) 2009-01-28 EP disclosed
EP-2012760-A2 PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS Novartis AG (CH) 2009-01-14 EP disclosed
EP-2013211-A2 PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS Novartis AG (CH) 2009-01-14 EP disclosed
EP-2013210-A1 PURINE DERIVATIVES WITH ACTIVITY TO THE ADENOSINE A2A RECEPTOR Novartis Ag (CH) 2009-01-14 EP disclosed
WO-2008152159-A2 6 -ACYLOXY- 7-METH0XY- 2, 2 -DIMETHYLCHROMANE COMPOUNDS AND THEIR USE AS PIGMENTATION-REGULATORS LIPOTEC, S.A. (ES) 2008-12-18 WO disclosed
WO-2008150015-A1 HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-11 WO disclosed
US-20080280871-A1 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases NOVARTIS AG (CH) 2008-11-13 US disclosed
EP-1979051-A2 TWO-COAT COSMETIC COMPOSITIONS AVON PRODUCTS, INC. (US) 2008-10-15 EP disclosed
US-20080242683-A1 Organic Compounds NOVARTIS AG (CH) 2008-10-02 US disclosed
WO-2008109424-A1 COMPOSITION, THERAPY AND DEVICE FOR TREATMENT OF NAIL INFECTIONS ONDINE INTERNATIONAL LTD. (BB) 2008-09-12 WO disclosed
US-7422793-B2 Non-toxic corrosion-protection rinses and seals based on rare earth elements UNIVERSITY OF DAYTON (US) 2008-09-09 US disclosed
US-20080200483-A1 Purine Derivatives for Use as Adenosin A-2A Receptor Agonists NOVARTIS AG (CH) 2008-08-21 US disclosed
US-7407711-B2 Non-toxic corrosion-protection conversion coats based on rare earth elements UNIVERSITY OF DAYTON (US) 2008-08-05 US disclosed
US-20080070929-A1 THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE ABBVIE INC. 2008-03-20 US disclosed
US-20080056996-A1 PHOTODYNAMIC THERAPY FOR THE TREATMENT OF HAIR LOSS QLT INC. (CA) 2008-03-06 US disclosed
US-20080015271-A1 Fatty acid pharmaceutical foam STIEFEL RESEARCH AUSTRIALIA PTY LTD (AU) 2008-01-17 US disclosed
WO-2008008397-A2 FATTY ACID PHARMACEUTICAL FOAM STIEFEL RESEARCH AUSTRALIA PTY LTD (AU) 2008-01-17 WO disclosed
WO-2008002956-A2 THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE ABBOTT LABORATORIES (US) 2008-01-03 WO disclosed
WO-2008000421-A2 THIAZOLYL UREA DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-03 WO disclosed
WO-2007140282-A1 PEG LINKER COMPOUNDS AND BIOLOGICALLY ACTIVE CONJUGATES THEREOF PEG BIOSCIENCES (US) 2007-12-06 WO disclosed
EP-1861412-A1 ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY Novartis AG (CH) 2007-12-05 EP disclosed
WO-2007134827-A1 5-PHENYL-THIAZ0L-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2007-11-29 WO disclosed
CN-101076514-A Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors ABIOGEN PHARMA SPA (IT) 2007-11-21 CN disclosed
US-7294211-B2 Non-toxic corrosion-protection conversion coats based on cobalt UNIVERSITY OF DAYTON (US) 2007-11-13 US disclosed
US-7291217-B2 Non-toxic corrosion-protection pigments based on rare earth elements UNIVERSITY OF DAYTON (US) 2007-11-06 US disclosed
WO-2007121919-A1 PURINE DERIVATIVES WITH ACTIVITY TO THE ADENOSINE A2A RECEPTOR NOVARTIS AG (CH) 2007-11-01 WO disclosed
WO-2007121920-A2 PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS NOVARTIS AG (CH) 2007-11-01 WO disclosed
WO-2007121921-A2 PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS NOVARTIS AG (CH) 2007-11-01 WO disclosed
WO-2007121918-A2 USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS NOVARTIS AG (CH) 2007-11-01 WO disclosed
US-7264629-B2 Photodynamic therapy for the treatment of hair loss QLT, INC. (CA) 2007-09-04 US disclosed
WO-2007079155-A2 TWO-COAT COSMETIC COMPOSITIONS AVON PRODUCTS, INC. (US) 2007-07-12 WO disclosed
EP-1805181-A1 PURINE DERIVATIVES FOR USE AS ADENOSIN A-2A RECEPTOR AGONISTS Novartis AG (CH) 2007-07-11 EP disclosed
US-20070149673-A1 NON-TOXIC CORROSION-PROTECTION PIGMENTS BASED ON MANGANESE STURGILL JEFFREY A 2007-06-28 US disclosed
US-7235142-B2 Non-toxic corrosion-protection rinses and seals based on cobalt UNIVERSITY OF DAYTON (US) 2007-06-26 US disclosed
US-20070087047-A1 Enhanced circulation effector composition and method ALZA CORPORATION 2007-04-19 US disclosed
US-20070059253-A1 Foamable pharmaceutical compositions and methods for treating a disorder STIEFEL LABORATORIES, INC. 2007-03-15 US disclosed
EP-1633368-A4 FOAMABLE PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING A DISORDER STIEFEL LABORATORIES (US) 2007-03-14 EP disclosed
WO-2007027328-A2 MICROBIAL SULFOXIDATION AND AMIDATION OF BENZHDRYLSULFANYL CARBOXYLIC ACIDS AND USES THEREOF UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2007-03-08 WO disclosed
US-7186416-B2 Foamable pharmaceutical compositions and methods for treating a disorder STIEFEL LABORATORIES, INC. (US) 2007-03-06 US disclosed
US-20070032487-A1 Inhibitors of phosphatidylinositol 3-kinase NOVARTIS AG (CH) 2007-02-08 US disclosed
US-20070026507-A1 MICROBIAL SULFOXIDATION AND AMIDATION OF BENZHDRYLSULFANYL CARBOXYLIC ACIDS AND USES THEREOF UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2007-02-01 US disclosed
US-7160554-B2 Enhanced circulation effector composition and method ALZA CORPORATION (US) 2007-01-09 US disclosed
US-7150882-B2 Enhanced circulation effector composition and method ALZA CORPORATION (US) 2006-12-19 US disclosed
US-20060265028-A1 Hair growth QLT INC. (CA) 2006-11-23 US disclosed
WO-2006097260-A1 ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY NOVARTIS AG (CH) 2006-09-21 WO disclosed
EP-1100454-A4 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR MANAGING SKIN CONDITIONS MURAD HOWARD (US) 2006-09-20 EP disclosed
EP-1689391-A2 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES Novartis AG (CH) 2006-08-16 EP disclosed
CN-1794998-A Foamable pharmaceutical compositions and methods for treating a disorder STIEFEL LABORATORIES (US) 2006-06-28 CN disclosed
WO-2006053172-A2 THE USE OF ESTRIOL AND OTHER ESTRANES, ESTROGENS AND ESTROGEN RECEPTOR ACTIVE COMPOSITIONS IN THE TREATMENT OF PSORIASIS AND OTHER AUTOIMMUNE DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-05-18 WO disclosed
WO-2006045552-A1 PURINE DERIVATIVES FOR USE AS ADENOSIN A-2A RECEPTOR AGONISTS NOVARTIS AG (CH) 2006-05-04 WO disclosed
US-20060083708-A1 Composition using mineral salts for cosmetic or therapeutic treatment MASADA MARKETING CORP. 2006-04-20 US disclosed
EP-1633368-A2 FOAMABLE PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING A DISORDER STIEFEL LABORATORIES, INC. (US) 2006-03-15 EP disclosed
EP-1622897-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE Novartis AG (CH) 2006-02-08 EP disclosed
EP-1617909-A1 HAIR GROWTH QLT Inc. (CA) 2006-01-25 EP disclosed
US-20050232957-A1 Compositions and methods for moisturizing skin TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE 2005-10-20 US disclosed
CN-1678569-A Photostable cationic organic sunscreen compounds and compositions obtained therefrom MERCK PATENT GMBH (DE) 2005-10-05 CN disclosed
US-20050209208-A1 Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-09-22 US disclosed
CN-1671759-A Copolymers and their use in personal care compositions CIBA SC HOLDING AG (CH) 2005-09-21 CN disclosed
EP-1228107-B1 ACRYLIC BLOCK COPOLYMER PIGMENT DISPERSANTS CONTAINING HETEROCYCLIC GROUPS DU PONT (US) 2005-07-13 EP disclosed
US-20050090481-A1 Compositions comprising a photosensitizer and a skin-penetration enhancer and their use in photodynamic treatment QLT INC 2005-04-28 US disclosed
CN-1198858-C Cationic polymers and their use BASF AG (DE) 2005-04-27 CN disclosed
WO-2005021519-A2 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES NOVARTIS AG (CH) 2005-03-10 WO disclosed
US-20040247663-A1 Liposomes with effector biomolecules attached to the distal ends of hydrophilic polymer chains provide increased time in the bloodstream; polymyxin B used for septic shock ALZA CORPORATION 2004-12-09 US disclosed
WO-2004105702-A2 FOAMABLE PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING A DISORDER STIEFEL LABORATORIES, INC. (US) 2004-12-09 WO disclosed
US-20040241099-A1 Foamable pharmaceutical compositions and methods for treating a disorder CONNETICS CORPORATION 2004-12-02 US disclosed
CN-1550520-A Polymer emulsions resistant to biodeterioration �����Ʒ�ۺ��﹫˾ 2004-12-01 CN disclosed
WO-2004096797-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE NOVARTIS AG (CH) 2004-11-11 WO disclosed
WO-2004093993-A1 HAIR GROWTH QLT INC. (CA) 2004-11-04 WO disclosed
EP-1472319-A1 NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT UNIVERSITY OF DAYTON (US) 2004-11-03 EP disclosed
WO-2004081034-A2 ALTERING METABOLISM IN BIOLOGICAL PROCESSES ADVANCED BIOCATALYTICS CORPORATION (US) 2004-09-23 WO disclosed
WO-2004065305-A1 NON-TOXIC CORROSION-PROTECTION PIGMENTS BASED ON MANGANESE UNIVERSITY OF DAYTON (US) 2004-08-05 WO disclosed
EP-1441767-A1 COMPOSITIONS COMPRISING A PHOTOSENSITIZER AND A SKIN-PENETRATION ENHANCER AND THEIR USE IN PHOTODYNAMIC TREATMENT QLT Inc. (CA) 2004-08-04 EP disclosed
US-20040120990-A1 Absorbent proteins and methods for using same CUSHMAN JOHN C (US) 2004-06-24 US disclosed
US-20040104377-A1 Non-toxic corrosion-protection pigments based on rare earth elements UNIVERSITY OF DAYTON 2004-06-03 US disclosed
US-20040029856-A1 Photodynamic therapy for the treatment of hair loss QLT INC. (CA) 2004-02-12 US disclosed
US-20040020568-A1 Non-toxic corrosion-protection conversion coats based on rare earth elements DAYTON, UNIVERSITY OF 2004-02-05 US disclosed
US-20040016910-A1 Non-toxic corrosion-protection rinses and seals based on rare earth elements DAYTON, UNIVERSITY OF 2004-01-29 US disclosed
US-20040011252-A1 Non-toxic corrosion-protection pigments based on manganese UNIVERSITY OF DAYTON 2004-01-22 US disclosed
US-20030234063-A1 Non-toxic corrosion-protection conversion coats based on cobalt DAYTON, UNIVERSITY OF 2003-12-25 US disclosed
US-20030230363-A1 Non-toxic corrosion-protection rinses and seals based on cobalt UNIVERSITY OF DAYTON 2003-12-18 US disclosed
US-20030198665-A1 Enhanced circulation effector composition and method ALZA CORPORATION 2003-10-23 US disclosed
WO-2003060191-A2 NON-TOXIC CORROSION-PROTECTION CONVERSION COATINGES ABSED ON COBALT UNIVERSITY OF DAYTON (US) 2003-07-24 WO disclosed
WO-2003060192-A1 NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT UNIVERSITY OF DAYTON (US) 2003-07-24 WO disclosed
WO-2003060019-A1 NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT UNIVERSITY OF DAYTON (US) 2003-07-24 WO disclosed
EP-1324681-A2 ARTICLE FOR THE DELIVERY OF FOAM PRODUCTS THE PROCTER & GAMBLE COMPANY (US) 2003-07-09 EP disclosed
US-6586002-B2 Slow down of renal clearance by parenterally administering a liposome having an outer layer of polyoxyethylene glycol chains; effectors, e.g., Fab fragments, CD4 glycoproteins, covalently attached to the distal ends of the polymer chain ALZA CORPORATION 2003-07-01 US disclosed
EP-1318801-A2 TOPICAL ANALGESIC COMPOSITIONS CONTAINING ALIPHATIC POLYAMINES AND METHODS OF USING SAME Dermal Therapy (Barbados) Inc. (BB) 2003-06-18 EP disclosed
WO-2003039597-A1 COMPOSITIONS COMPRISING A PHOTOSENSITIZER AND A SKIN-PENETRATION ENHANCER AND THEIR USE IN PHOTODYNAMIC TREATMENT QLT INC. (CA) 2003-05-15 WO disclosed
US-6547063-B1 Article for the delivery of foam products THE PROCTER & GAMBLE COMPANY 2003-04-15 US disclosed
EP-1228107-A1 ACRYLIC BLOCK COPOLYMER PIGMENT DISPERSANTS CONTAINING HETEROCYCLIC GROUPS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2002-08-07 EP disclosed
WO-2002030237-A2 ARTICLE FOR THE DELIVERY OF FOAM PRODUCTS THE PROCTER & GAMBLE COMPANY (US) 2002-04-18 WO disclosed
EP-1194437-A1 DIPHOSPHINE LIGANDS FOR METAL COMPLEXES Solvias AG (CH) 2002-04-10 EP disclosed
WO-2002024185-A2 TOPICAL ANALGESIC COMPOSITIONS CONTAINING ALIPHATIC POLYAMINES AND METHODS OF USING SAME DERMAL THERAPY (BARBADOS) INC. (BB) 2002-03-28 WO disclosed
WO-2002022115-A2 METHODS AND COMPOSITIONS FOR TREATING NAIL FUNGUS THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK AT STONY BROOK (US) 2002-03-21 WO disclosed
US-20020012697-A1 COSMETIC AND TISSUE CLEANSING AND MOISTURIZING COMPOSITION SCHWARTZ SAM (US) 2002-01-31 US disclosed
EP-1169017-A1 ANTIMICROBIAL WIPES THE PROCTER & GAMBLE COMPANY (US) 2002-01-09 EP disclosed
US-6326353-B1 123THERAPY FOR SEPTIC SHOCK; ADMINISTERING POLYMYXIN BY INJECTION SEQUUS PHARMACEUTICALS, INC. 2001-12-04 US disclosed
US-20010043929-A1 Enhanced circulation effector composition and method ALZA CORPORATION 2001-11-22 US disclosed
US-6316564-B1 FACILITATE ATTACHMENT ON A PIGMENT SURFACE AND IMPROVE DISPERSANT EFFICIENCY IN SOLVENT-BORNE PAINT SYSTEMS E. I. DU PONT DE NEMOURS AND COMPANY 2001-11-13 US disclosed
CN-1313870-A Cationic polymers and their use BASF AG (DE) 2001-09-19 CN disclosed
US-6283336-B1 Article for the delivery of foam products THE PROCTER & GAMBLE COMPANY 2001-09-04 US disclosed
EP-1100454-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR MANAGING SKIN CONDITIONS Murad, Howard (US) 2001-05-23 EP disclosed
WO-2001025292-A1 ACRYLIC BLOCK COPOLYMER PIGMENT DISPERSANTS CONTAINING HETEROCYCLIC GROUPS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2001-04-12 WO disclosed
WO-2001012133-A2 COSMETIC COMPOSITIONS WITH SELF-WARMING COMPONENT UNILEVER PLC (GB) 2001-02-22 WO disclosed
EP-1074245-A2 Composition using mineral salts for therapeutic treatment Schwartz, Sam (US) 2001-02-07 EP disclosed
US-6180134-B1 FOR TREATING SUBJECT WITH SMALL EFFECTOR MOLECULES WHICH ARE NORMALLY SUBJECT TO RAPID RENAL CLEARANCE FROM BLOODSTREAM; FOR TREATING SEPTIC SHOCK, FOR USE IN TREATING INFLAMMATION RELATED TO NEUTROPHIL RECRUITMENT AND TISSUE INFILTRATION SEQUUS PHARMACEUTICALS, INC. 2001-01-30 US disclosed
WO-2001004131-A1 DIPHOSPHINE LIGANDS FOR METAL COMPLEXES SOLVIAS AG (CH) 2001-01-18 WO disclosed
WO-2000061107-A1 ANTIMICROBIAL THE PROCTER & GAMBLE COMPANY (US) 2000-10-19 WO disclosed
WO-2000006116-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR MANAGING SKIN CONDITIONS MURAD HOWARD (US) 2000-02-10 WO disclosed
WO-1999055815-A1 IMPROVED UNCOMPLEXED CYCLODEXTRIN COMPOSITIONS FOR ODOR CONTROL THE PROCTER & GAMBLE COMPANY (US) 1999-11-04 WO disclosed
EP-0937453-A2 Cosmetic and tissue cleansing and moisturizing composition Schwartz, Sam (US) 1999-08-25 EP disclosed
EP-0804285-B1 ENCAPSULATED ACTIVE MATERIALS AND METHOD FOR PREPARING SAME DOW CHEMICAL CO (US) 1999-07-28 EP disclosed
US-5922331-A PROTECTION AGAINST LUMPINESS, EDEMA AND OTHER EFFECTS FO LIPOSUCTION AND COSMETIC SURGERY CHANEL, INC. (US) 1999-07-13 US disclosed
EP-0907352-A1 METHOD AND COMPOSITION FOR SKIN LIGHTENING UNILEVER PLC (GB) 1999-04-14 EP disclosed
EP-0689428-B1 ENHANCED CIRCULATION EFFECTOR COMPOSITION AND METHOD SEQUUS PHARM INC (US) 1999-01-20 EP disclosed
WO-1998058731-A2 APPARATUS FOR EXPOSING SUBSTRATES TO GAS-PHASE RADICALS FLOWGENIX CORPORATION (US) 1998-12-30 WO disclosed
EP-0855895-A1 LIQUID CRYSTAL COSMETIC COMPOSITION UNILEVER PLC (GB) 1998-08-05 EP disclosed
WO-1998032790-A1 POROUS ARTICLES WITH SURFACE FUNCTIONALITY AND USES THEREOF FLOWGENIX CORPORATION (US) 1998-07-30 WO disclosed
WO-1997047280-A1 METHOD AND COMPOSITION FOR SKIN LIGHTENING UNILEVER PLC (GB) 1997-12-18 WO disclosed
EP-0804285-A1 ENCAPSULATED ACTIVE MATERIALS AND METHOD FOR PREPARING SAME THE DOW CHEMICAL COMPANY (US) 1997-11-05 EP disclosed
WO-1997014394-A1 LIQUID CRYSTAL COSMETIC COMPOSITION UNILEVER PLC (GB) 1997-04-24 WO disclosed
US-5620689-A ADMINISTERING A SUSPENSION OF LIPOSOMES HAVING A SURFACE COATING OF POLYETHYLENE GLYCOL CHAINS SEQUUS PHARMACEUUTICALS, INC. (US) 1997-04-15 US disclosed
EP-0761658-A1 Azole-phenyl urea derivatives as ACAT inhibitors and their production NIHON NOHYAKU CO., LTD. (JP) 1997-03-12 EP disclosed
US-5601761-A Encapsulated active materials and method for preparing same THE DOW CHEMICAL COMPANY (US) 1997-02-11 US disclosed
US-5527528-A INJECTING LIPOSOMES, CONTAINING ANTITUMOR AGENT, WITH COATING OF ENDCAPPED POLYETHYLENE GLYCOL AND ANTIBODIES TO BIND TUMOR-ASSOCIATED ANTIGENS SEQUUS PHARMACEUTICALS, INC. (US) 1996-06-18 US disclosed
WO-1996009883-A1 ENCAPSULATED ACTIVE MATERIALS AND METHOD FOR PREPARING SAME THE DOW CHEMICAL COMPANY (US) 1996-04-04 WO disclosed
EP-0689428-A1 ENHANCED CIRCULATION EFFECTOR COMPOSITION AND METHOD SEQUUS PHARMACEUTICALS, INC. (US) 1996-01-03 EP disclosed
WO-1994022429-A1 SOLID-TUMOR TREATMENT METHOD LIPOSOME TECHNOLOGY, INC. (US) 1994-10-13 WO disclosed
WO-1994021235-A1 ENHANCED CIRCULATION EFFECTOR COMPOSITION AND METHOD LIPOSOME TECHNOLOGY, INC. (US) 1994-09-29 WO disclosed
WO-1994021281-A1 POLYMER-POLYPEPTIDE COMPOSITION AND METHOD LIPOSOME TECHNOLOGY, INC. (US) 1994-09-29 WO disclosed
US-5276038-A 1-aryl-3-(3,4-dihydro-4-oxo-3-quinazolinyl)urea fungicidal agents AMERICAN CYANAMID COMPANY (US) 1994-01-04 US disclosed
EP-0282050-B1 CARBONYL- AND SULPHONYL- DERIVATIVES OF 2-(AMINOALKYLTHIO)- METHYL-1,4-DIHYDROPYRIDINES, A METHOD FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1993-10-06 EP disclosed
US-4968732-A POLYEPOXIDE PREPREGS SCHERING AKTIENGESELLSCHAFT (DE) 1990-11-06 US disclosed
US-4968732-A POLYEPOXIDE PREPREGS SCHERING AKTIENGESELLSCHAFT (DE) 1990-11-06 US disclosed
US-4931529-A DICYANDIAMIDE AS HARDENER SCHERING AKTIENGESELLSCHAFT (DE) 1990-06-05 US disclosed
US-4931529-A DICYANDIAMIDE AS HARDENER SCHERING AKTIENGESELLSCHAFT (DE) 1990-06-05 US disclosed
EP-0344468-A1 Imidazolyl-urea compounds and their use as hardening accelerators in epoxy resin compositions for the production of shaped articles Witco GmbH (DE) 1989-12-06 EP disclosed
EP-0344468-A1 Imidazolyl-urea compounds and their use as hardening accelerators in epoxy resin compositions for the production of shaped articles Witco GmbH (DE) 1989-12-06 EP disclosed
EP-0282050-A1 Carbonyl- and sulphonyl- derivatives of 2-(aminoalkylthio)- methyl-1,4-dihydropyridines, a method for their preparation and pharmaceutical compositions containing them BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1988-09-14 EP disclosed
JP-S6330471-A NOVEL IMIDAZOLEUREA COMPOUND, SYNTHESIS THEREOF AND CURING METHOD FOR POLYEPOXY RESIN USING SAID COMPOUND SHIKOKU CHEM CORP 1988-02-09 JP disclosed
EP-0029663-B1 N-ARYL-N'-IMIDAZOL-2-YLUREAS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM McNeilab, Inc. (US) 1984-04-18 EP disclosed
US-4412079-A HERBICIDES, INSECTICIDES, FUNGICIDES, MITICIDES AIR PRODUCTS AND CHEMICALS, INC. (US) 1983-10-25 US disclosed
EP-0029663-A1 N-aryl-N'-imidazol-2-ylureas, process for their preparation and pharmaceutical compositions containing them McNeilab, Inc. (US) 1981-06-03 EP disclosed
US-4265900-A HYPOTENSIVE, ANTISECRETORY, ANTIDIARRHEA MCNEILAB, INC. (US) 1981-05-05 US disclosed
US-3972706-A SUBSTITUTED THIADIAZOL-2-YL-UREAS ELI LILLY AND COMPANY (US) 1976-08-03 US disclosed
US-3972706-A SUBSTITUTED THIADIAZOL-2-YL-UREAS ELI LILLY AND COMPANY (US) 1976-08-03 US disclosed